The Company will issue a release after the oral presentation that will include the 5-year OS data, which is the longest OS follow-up in a randomized trial in metastatic uveal melanoma patients. Beyond ...

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

Adding the immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab to percutaneous hepatic perfusion may improve survival outcomes in patients with ...

One treatment-related death occurred in the combination therapy group.

IDEAYA Biosciences (NASDAQ:IDYA) executives outlined multiple upcoming clinical catalysts at Citi’s 2026 Virtual Oncology Leadership Summit, led by an end-of-March top-line readout for the company’s ...

Immatics N.V. remains a speculative Buy, driven by progress with anzu-cel in 2L melanoma and a robust cell therapy pipeline.

A study led by Dr. J. William Harbour of UT Southwestern Medical Center marks a shift in how doctors predict the spread of uveal melanoma. A recent study led by Dr. J. William Harbour of UT ...

IDEAYA Biosciences (NASDAQ:IDYA) outlined upcoming clinical milestones for its precision oncology pipeline, emphasizing an imminent top-line readout in first-line metastatic uveal melanoma (MUM), ...

Syncona’s maturing portfolio entering a period of significant clinical and strategic milestones, positioning the business for near-term value creation and enabling returns to shareholdersHigh-calibre ...

PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from the FDA for the treatment of ...

Explore the hidden economic burdens of eye cancer in India and the urgent need for awareness, access, and specialized care.